PAREXEL board approves stock repurchase program

PAREXEL International Corporation (Nasdaq: PRXL) announced today that its Board of Directors has approved a stock repurchase program authorizing the repurchase of up to $200 million of the Company's common stock, subject to the consent of the Company's lenders.  There is no set expiration date for the program. 

The Company intends to use cash on hand, cash generated from operations, existing credit facilities, or other financing to fund the share repurchase program.  As of June 30, 2012, the Company had cash and cash equivalents of approximately $214 million, and availability under its existing lines of credit of $175 million. 

The program does not obligate the Company to acquire any particular amount of common stock, and it could be modified, extended, suspended or discontinued at any time. 

The timing and amount of repurchases will be determined by PAREXEL's management based on a variety of factors such as trading price, corporate requirements, and overall market conditions, and will be subject to applicable legal requirements including federal and state securities laws.  Purchases will be made in open market transactions effected through a broker dealer at prevailing market prices, in block trades, or in privately negotiated transactions.  Shares may also be purchased pursuant to a trading plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so under insider trading laws. 

The Company had approximately $6 million remaining under a previous stock repurchase program, which has now been canceled.  As of June 30, 2012, PAREXEL had approximately 60.1 million common shares outstanding.

Mr. Josef von Rickenbach, Chairman and CEO of PAREXEL stated, "We are committed to optimizing the capital structure of the Company and to creating and enhancing shareholder value.  We're pleased that the strength of our business fundamentals allows us to demonstrate our confidence through this stock repurchase program.  We remain positive about the long-term growth and profitability opportunities that lie ahead of us, and look forward to keeping shareholders apprised of our progress."

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Parexel. (2019, June 20). PAREXEL board approves stock repurchase program. News-Medical. Retrieved on December 24, 2024 from https://www.news-medical.net/news/20120809/PAREXEL-board-approves-stock-repurchase-program.aspx.

  • MLA

    Parexel. "PAREXEL board approves stock repurchase program". News-Medical. 24 December 2024. <https://www.news-medical.net/news/20120809/PAREXEL-board-approves-stock-repurchase-program.aspx>.

  • Chicago

    Parexel. "PAREXEL board approves stock repurchase program". News-Medical. https://www.news-medical.net/news/20120809/PAREXEL-board-approves-stock-repurchase-program.aspx. (accessed December 24, 2024).

  • Harvard

    Parexel. 2019. PAREXEL board approves stock repurchase program. News-Medical, viewed 24 December 2024, https://www.news-medical.net/news/20120809/PAREXEL-board-approves-stock-repurchase-program.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CenterWatch 2017 Global Investigative Site Relationship Survey ranks PAREXEL among top five CROs